Li Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Li Lin has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Ying Sun
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
15 shared publications Chen-Fei Wu
6 shared publicationsYing Sun
Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China
6 shared publicationsGuan-Qun Zhou
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
5 shared publications- Guan-Qun Zhou
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
5 shared publications Jia Kou
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
5 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Springer Nature in npj Precision Oncology
A scalable AI framework for automated TNM staging of 51,242 patients with nasopharyngeal carcinoma
- 4 September 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessA scalable AI framework for automated TNM staging of 51,242 patients with nasopharyngeal carcinoma
- 15 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (858) , eaec4847
Culturomics reveals Fusobacterium-Prevotella mutualism as a hallmark of nasopharyngeal tumor microbiota.
The nasopharynx constitutes a critical niche in the upper respiratory tract, harboring a diverse microbiota linked to nasopharyngeal carcinoma (NPC), the mechanistic roles of which remain poorly understood. Here, we established the Nasopharyngeal Mucosal and Tumor-resident Bacterial Catalog (NMTBC) that comprises 5311 bacterial isolates representing 127 species, with 1006 of them being fully sequenced and annotated, providing a comprehensive culturable resource facilitating mechanistic dissection of the microbiome-tumor interactions. With NMTBC, we uncovered a Fusobacterium-Prevotella mutualism and revealed heterotypic bacterium-bacterium interactions involving transcriptional reprogramming and metabolic cross-talk. Using single-bacterial transcriptomics, we mapped a high-resolution transcriptomic trajectory, showing the ability of a single strain to differentiate into functionally distinct subpopulations that cooperate to sustain mutualism. By analyzing a multicenter NPC cohort, we showed that Fusobacterium and Prevotella co-colonization in NPC tumors correlated with unfavorable clinical outcomes after conventional radiochemotherapy. Analysis of RNA-seq data from two previous phase 3 clinical trials showed that coenrichment of Fusobacterium-Prevotella predicted better response to anti-PD-1 immunotherapy, highlighting their important role in microbiota-mediated immunomodulation. Overall, this study establishes a comprehensive nasopharyngeal bacterial catalog through culturomics, which offers valuable insights into microbiome-derived biomarker discovery and immunotherapy patient stratification in clinical practice.
- 15 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (858) , eaec4847
Culturomics reveals Fusobacterium-Prevotella mutualism as a hallmark of nasopharyngeal tumor microbiota.
The nasopharynx constitutes a critical niche in the upper respiratory tract, harboring a diverse microbiota linked to nasopharyngeal carcinoma (NPC), the mechanistic roles of which remain poorly understood. Here, we established the Nasopharyngeal Mucosal and Tumor-resident Bacterial Catalog (NMTBC) that comprises 5311 bacterial isolates representing 127 species, with 1006 of them being fully sequenced and annotated, providing a comprehensive culturable resource facilitating mechanistic dissection of the microbiome-tumor interactions. With NMTBC, we uncovered a Fusobacterium-Prevotella mutualism and revealed heterotypic bacterium-bacterium interactions involving transcriptional reprogramming and metabolic cross-talk. Using single-bacterial transcriptomics, we mapped a high-resolution transcriptomic trajectory, showing the ability of a single strain to differentiate into functionally distinct subpopulations that cooperate to sustain mutualism. By analyzing a multicenter NPC cohort, we showed that Fusobacterium and Prevotella co-colonization in NPC tumors correlated with unfavorable clinical outcomes after conventional radiochemotherapy. Analysis of RNA-seq data from two previous phase 3 clinical trials showed that coenrichment of Fusobacterium-Prevotella predicted better response to anti-PD-1 immunotherapy, highlighting their important role in microbiota-mediated immunomodulation. Overall, this study establishes a comprehensive nasopharyngeal bacterial catalog through culturomics, which offers valuable insights into microbiome-derived biomarker discovery and immunotherapy patient stratification in clinical practice.
- 8 July 2026
- Published by Springer Nature in Molecular Imaging and Biology
- p. 1-13
LLM-Enhanced Multimodal Fusion of SPECT Radiomics and Clinical Data for Predicting 131I Therapeutic Response in Differentiated Thyroid Cancer
Background Patients with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) remain at risk of adverse outcomes. Early prediction of RAI efficacy is critical for optimizing clinical management. Purpose To develop a model integrating Single Photon Emission Computed Tomography (SPECT) radiomic features and clinical variables for predicting the therapeutic efficacy of 131I treatment in patients with DTC. Materials and Method The SPECT images and clinical data from 311 patients were included in this study. A total of 1,688 radiomic features were extracted from SPECT images. We investigated the diagnostic performance of 30 cross-combined models. Radiomic features were then combined with clinical parameters using early-fusion and late-fusion strategies. To further enhance predictive performance, an input sequence reflecting the selected features and the prediction task was designed and fed into a selected Large Language Model (LLM), which was fine-tuned using low-rank adaptation to optimize fused feature representations. Model performance was evaluated using accuracy (Acc), sensitivity (Sens), positive predictive value (PPV), F1-score, and the area under the curve (AUC). Results The Relief-F + random forest radiomic model achieved the highest AUC (0.69). Multimodal models combining radiomics with clinical features outperformed clinical-only models, demonstrating the added predictive value of radiomics. The final LLM-enhanced multimodal model achieved the best performance, with an AUC of 0.85 and notable improvements in sensitivity and F1-score. Conclusions The proposed multimodal framework provides accurate early prediction of RAI therapeutic response in DTC and holds promise for improving individualized treatment planning and follow-up strategies.
- 8 July 2026
- Published by Springer Nature in Molecular Imaging and Biology
- p. 1-13
LLM-Enhanced Multimodal Fusion of SPECT Radiomics and Clinical Data for Predicting 131I Therapeutic Response in Differentiated Thyroid Cancer
Background Patients with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) remain at risk of adverse outcomes. Early prediction of RAI efficacy is critical for optimizing clinical management. Purpose To develop a model integrating Single Photon Emission Computed Tomography (SPECT) radiomic features and clinical variables for predicting the therapeutic efficacy of 131I treatment in patients with DTC. Materials and Method The SPECT images and clinical data from 311 patients were included in this study. A total of 1,688 radiomic features were extracted from SPECT images. We investigated the diagnostic performance of 30 cross-combined models. Radiomic features were then combined with clinical parameters using early-fusion and late-fusion strategies. To further enhance predictive performance, an input sequence reflecting the selected features and the prediction task was designed and fed into a selected Large Language Model (LLM), which was fine-tuned using low-rank adaptation to optimize fused feature representations. Model performance was evaluated using accuracy (Acc), sensitivity (Sens), positive predictive value (PPV), F1-score, and the area under the curve (AUC). Results The Relief-F + random forest radiomic model achieved the highest AUC (0.69). Multimodal models combining radiomics with clinical features outperformed clinical-only models, demonstrating the added predictive value of radiomics. The final LLM-enhanced multimodal model achieved the best performance, with an AUC of 0.85 and notable improvements in sensitivity and F1-score. Conclusions The proposed multimodal framework provides accurate early prediction of RAI therapeutic response in DTC and holds promise for improving individualized treatment planning and follow-up strategies.
- Open Access
- 29 April 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (5) , 521
Habitat Analysis for Risk Prediction of Nasopharyngeal Carcinoma: A Comparative Study of Different MRI Sequences and Regional Combinations
Habitat analysis enables spatial characterization of intratumoral heterogeneity; however, its application in nasopharyngeal carcinoma (NPC), particularly regarding metastatic lymph node (MLN), remains limited. This study aims to systematically compare the prognostic performance of various models using different sequences and spatial region combinations for predicting overall survival in NPC. The study retrospectively included 725 NPC patients (543 training, 182 testing). Habitat analysis was conducted based on T1, T1C, and T2 sequences in three regional strategies: primary gross tumor volume (GTVp), metastatic lymph nodes (MLNs), and the combined region of GTVp-MLN. The tumor area was divided into six subregions, and a multi-region spatial interaction (MSI) matrix was constructed to extract MSI features. On this basis, a radiomics model (R Model) and a clinical–radiomics model (CR Model) were established, and the model performance was evaluated using C-index and Kaplan–Meier survival analysis. The results show that the combined GTVp-MLN model based on the T1 sequence achieved the best overall predictive performance (R Model: C-index = 0.693; CR Model: C-index = 0.722). Significant survival differences were observed between the high- and low-risk groups. These findings suggest that habitat analysis incorporating the combined GTVp–MLN region may improve prognostic prediction and risk stratification in patients with NPC.
- 29 April 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (5) , 521
Open AccessHabitat Analysis for Risk Prediction of Nasopharyngeal Carcinoma: A Comparative Study of Different MRI Sequences and Regional Combinations
Habitat analysis enables spatial characterization of intratumoral heterogeneity; however, its application in nasopharyngeal carcinoma (NPC), particularly regarding metastatic lymph node (MLN), remains limited. This study aims to systematically compare the prognostic performance of various models using different sequences and spatial region combinations for predicting overall survival in NPC. The study retrospectively included 725 NPC patients (543 training, 182 testing). Habitat analysis was conducted based on T1, T1C, and T2 sequences in three regional strategies: primary gross tumor volume (GTVp), metastatic lymph nodes (MLNs), and the combined region of GTVp-MLN. The tumor area was divided into six subregions, and a multi-region spatial interaction (MSI) matrix was constructed to extract MSI features. On this basis, a radiomics model (R Model) and a clinical–radiomics model (CR Model) were established, and the model performance was evaluated using C-index and Kaplan–Meier survival analysis. The results show that the combined GTVp-MLN model based on the T1 sequence achieved the best overall predictive performance (R Model: C-index = 0.693; CR Model: C-index = 0.722). Significant survival differences were observed between the high- and low-risk groups. These findings suggest that habitat analysis incorporating the combined GTVp–MLN region may improve prognostic prediction and risk stratification in patients with NPC.
- Open Access
- 2 March 2026
- Published by Elsevier in SSRN Electronic Journal
Lymph Node Distribution Patterns and Clinical Target Volume Optimization in the Supraclavicular Region: A Large-scale Study of Five Head and Neck, and Thoracic Cancers
Purpose : To characterize the lymph node (LN) distribution difference in the supraclavicular region across five cancers—nasopharyngeal carcinoma (NPC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer (EC), lung cancer (LC), and breast cancer (BC), thereby guiding clinical target volume (CTV) optimization.Materials and Methods : We conducted a retrospective analysis of 1,900 patients with supraclavicular LN metastasis, including 700 with NPC and 300 each with HNSCC, EC, LC, and BC. LNs with short-axis diameter ³4 mm were marked on a template computed tomography scan. LN distribution probability maps and distribution curves were established for visualization and were analyzed against the 2013 consensus guidelines to propose CTV modifications.Result s : A total of 2533 (NPC), 727 (HNSCC), 932 (EC), 705 (LC), and 1091 (BC) supraclavicular LNs were marked, enabling constrution of distribution probability maps and distribution curves. Overall, most LNs fell within the guidelines-defined levels. Level Ⅳa was the most common site across all cancers, level Ⅵb being particularly frequent in EC and LC, while BC-derived LNs often existed caudally in levels Ⅳb and Ⅴc. No LNs emerged in level Ⅵa. Crucially, subregions within levels Ⅳ and Ⅴc showed minimal LN involvement, whereas LNs exceeded the posterior boundaries of levels Ⅴb and Ⅴc in 28.6% (200 of 700) of NPC, 5.3% (16 of 300) of HNSCC, 0.7% (2 of 300) of EC, 2.7% (8 of 300) of LC, and 20.9% (62 of 300) of BC patients. These findings support cancer-specific and risk-adapted reduction of the boundaries in levels Ⅳ and Ⅴc and posterior extension in levels Ⅴb and Ⅴc.Conclusion s : This study demonstrates LN distribution patterns in the supraclavicular region. We propose CTV optimization in levels Ⅳ, Ⅴb and Ⅴc.
- 2 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLymph Node Distribution Patterns and Clinical Target Volume Optimization in the Supraclavicular Region: A Large-scale Study of Five Head and Neck, and Thoracic Cancers
Purpose : To characterize the lymph node (LN) distribution difference in the supraclavicular region across five cancers—nasopharyngeal carcinoma (NPC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer (EC), lung cancer (LC), and breast cancer (BC), thereby guiding clinical target volume (CTV) optimization.Materials and Methods : We conducted a retrospective analysis of 1,900 patients with supraclavicular LN metastasis, including 700 with NPC and 300 each with HNSCC, EC, LC, and BC. LNs with short-axis diameter ³4 mm were marked on a template computed tomography scan. LN distribution probability maps and distribution curves were established for visualization and were analyzed against the 2013 consensus guidelines to propose CTV modifications.Result s : A total of 2533 (NPC), 727 (HNSCC), 932 (EC), 705 (LC), and 1091 (BC) supraclavicular LNs were marked, enabling constrution of distribution probability maps and distribution curves. Overall, most LNs fell within the guidelines-defined levels. Level Ⅳa was the most common site across all cancers, level Ⅵb being particularly frequent in EC and LC, while BC-derived LNs often existed caudally in levels Ⅳb and Ⅴc. No LNs emerged in level Ⅵa. Crucially, subregions within levels Ⅳ and Ⅴc showed minimal LN involvement, whereas LNs exceeded the posterior boundaries of levels Ⅴb and Ⅴc in 28.6% (200 of 700) of NPC, 5.3% (16 of 300) of HNSCC, 0.7% (2 of 300) of EC, 2.7% (8 of 300) of LC, and 20.9% (62 of 300) of BC patients. These findings support cancer-specific and risk-adapted reduction of the boundaries in levels Ⅳ and Ⅴc and posterior extension in levels Ⅴb and Ⅴc.Conclusion s : This study demonstrates LN distribution patterns in the supraclavicular region. We propose CTV optimization in levels Ⅳ, Ⅴb and Ⅴc.
- 1 February 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 7 (2) , e230544
A Serial MRI–based Deep Learning Model to Predict Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
A prognostic model incorporating pre- and posttreatment serial MRI acquisitions and clinical factors using deep learning methods showed good performance in survival prediction and risk stratification of patients with locoregionally advanced nasopharyngeal carcinoma.
- 1 February 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Artificial Intelligence
- Vol. 7 (2) , e230544
A Serial MRI–based Deep Learning Model to Predict Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
A prognostic model incorporating pre- and posttreatment serial MRI acquisitions and clinical factors using deep learning methods showed good performance in survival prediction and risk stratification of patients with locoregionally advanced nasopharyngeal carcinoma.
- 8 February 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103103
Cross-site prognosis prediction for nasopharyngeal carcinoma from incomplete multi-modal data
- 8 February 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 93, 103103
Cross-site prognosis prediction for nasopharyngeal carcinoma from incomplete multi-modal data
- Open Access
- 29 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104873
m6A-enriched lncRNA LINC00839 promotes tumor progression by enhancing TAF15-mediated transcription of amine oxidase AOC1 in nasopharyngeal carcinoma
- 29 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104873
Open Accessm6A-enriched lncRNA LINC00839 promotes tumor progression by enhancing TAF15-mediated transcription of amine oxidase AOC1 in nasopharyngeal carcinoma
- Open Access
- 29 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-14
Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
Purpose: The aims of this study focusing on Locoregionally advanced nasopharyngeal carcinoma (LANPC) were mainly two-fold: on the one hand, to establish a cut-off value to differentiate early and late failure based on prognosis after recurrence or metastasis; and on the other hand, to investigate the duration of concurrent cisplatin benefit over follow-up time. The results of our study have the potential to guide clinical practice and follow-up. Methods: In total, 3123 patients with stage III-IVa NPC receiving Induction chemotherapy followed by concurrent cisplatin or not were analysed. The cut-off value of treatment failure was calculated using the minimum P-value approach. Random survival forest (RSF) model was to simulate the cumulative probabilities of treatment failure (locoregional recurrence and /or distant metastasis) over-time, as well as the monthly time-specific, event-occurring probabilities, for patients at different treatment groups. Results: Based on subsequent prognosis, early locoregional failure (ELRF) should be defined as recurrence within 14 months (P = 1.47 × 10 − 3), and early distant failure (EDF) should be defined as recurrence within 20 months (P = 1.95 × 10 − 4). A cumulative cisplatin dose (CCD) > 200 mg/m2 independently reduced the risk of EDF (hazard ratio, 0.351; 95% confidence interval (CI), 0.169–0.732; P = 0.005). Better failure-free survival (FFS) and overall survival (OS) were observed in concurrent chemotherapy settings ([0 mg/m2 vs. 1-200 mg/m2 vs. >200 mg/m2]: FFS: 70.4% vs. 74.4% vs. 82.6%, all P < 0.03; OS: 79.5% vs. 83.8% vs. 90.8%, all P < 0.01). In the monthly analysis, treatment failure mainly occurred during the first 4 years, and the risk of distant failure in patients treated with concurrent chemotherapy never exceeded that of patients without concurrent chemotherapy. Conclusion: Locoregional failure that developed within 14 months and/or distant failure within 20 months had poorer subsequent survival. Concurrent chemotherapy provides a significant FFS benefit, primarily by reducing EDF, translating into a long-term OS benefit.
- 29 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-14
Open AccessCisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
Purpose: The aims of this study focusing on Locoregionally advanced nasopharyngeal carcinoma (LANPC) were mainly two-fold: on the one hand, to establish a cut-off value to differentiate early and late failure based on prognosis after recurrence or metastasis; and on the other hand, to investigate the duration of concurrent cisplatin benefit over follow-up time. The results of our study have the potential to guide clinical practice and follow-up. Methods: In total, 3123 patients with stage III-IVa NPC receiving Induction chemotherapy followed by concurrent cisplatin or not were analysed. The cut-off value of treatment failure was calculated using the minimum P-value approach. Random survival forest (RSF) model was to simulate the cumulative probabilities of treatment failure (locoregional recurrence and /or distant metastasis) over-time, as well as the monthly time-specific, event-occurring probabilities, for patients at different treatment groups. Results: Based on subsequent prognosis, early locoregional failure (ELRF) should be defined as recurrence within 14 months (P = 1.47 × 10 − 3), and early distant failure (EDF) should be defined as recurrence within 20 months (P = 1.95 × 10 − 4). A cumulative cisplatin dose (CCD) > 200 mg/m2 independently reduced the risk of EDF (hazard ratio, 0.351; 95% confidence interval (CI), 0.169–0.732; P = 0.005). Better failure-free survival (FFS) and overall survival (OS) were observed in concurrent chemotherapy settings ([0 mg/m2 vs. 1-200 mg/m2 vs. >200 mg/m2]: FFS: 70.4% vs. 74.4% vs. 82.6%, all P < 0.03; OS: 79.5% vs. 83.8% vs. 90.8%, all P < 0.01). In the monthly analysis, treatment failure mainly occurred during the first 4 years, and the risk of distant failure in patients treated with concurrent chemotherapy never exceeded that of patients without concurrent chemotherapy. Conclusion: Locoregional failure that developed within 14 months and/or distant failure within 20 months had poorer subsequent survival. Concurrent chemotherapy provides a significant FFS benefit, primarily by reducing EDF, translating into a long-term OS benefit.
- Open Access
- 27 October 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5384-5396
Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases
Objectives: The time for posttreatment tumor progression differs between nasopharyngeal carcinoma (NPC) patients. Herein, we established effective nomograms for predicting early tumor progression (ETP) and late tumor progression (LTP) in NPC patients.Methods: We retrospectively enrolled 8292 NPC patients (training cohort: n = 6219; validation cohort: n = 2073). The ELP and LTP were defined as the time to tumor progression ≤24 and >24 months after treatment, respectively.Results: The ETP and LTP accounted for 52.6 and 47.4% of the total patient cohort, respectively. Patients who developed ETP had markedly worse overall survival (OS) versus patients who suffered from LTP (5‐year OS: 26.2% vs. 59.7%, p < 0.001). Further, we identified 10/6 predictive factors significantly associated with ETP/LTP via logistic regression analyses. These indicators were used separately to construct two predictive nomograms for ETP and LTP. In the training group, the ETP nomogram [Harrell Concordance Index (C‐index) value: 0.711 vs. 0.618; p < 0.001] and LTP nomogram (C‐index value: 0.701 vs. 0.612; p < 0.001) were significantly superior for risk stratification than the TNM staging. These results were supported in the validation group with a C‐index value of 0.753 and 0.738 for the ETP and LTP nomograms, respectively. High‐risk patients defined by ETP/LTP nomograms had shorter progression‐free survival than low‐risk patients (all p < 0.001).Conclusion: The established nomograms can help in ELP or LTP risk stratification for NPC patients. Our current results might also provide insights into individualized treatment decisions and designing surveillance strategies for NPC patients.
- 27 October 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (5) , 5384-5396
Open AccessPrognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases
Objectives: The time for posttreatment tumor progression differs between nasopharyngeal carcinoma (NPC) patients. Herein, we established effective nomograms for predicting early tumor progression (ETP) and late tumor progression (LTP) in NPC patients.Methods: We retrospectively enrolled 8292 NPC patients (training cohort: n = 6219; validation cohort: n = 2073). The ELP and LTP were defined as the time to tumor progression ≤24 and >24 months after treatment, respectively.Results: The ETP and LTP accounted for 52.6 and 47.4% of the total patient cohort, respectively. Patients who developed ETP had markedly worse overall survival (OS) versus patients who suffered from LTP (5‐year OS: 26.2% vs. 59.7%, p < 0.001). Further, we identified 10/6 predictive factors significantly associated with ETP/LTP via logistic regression analyses. These indicators were used separately to construct two predictive nomograms for ETP and LTP. In the training group, the ETP nomogram [Harrell Concordance Index (C‐index) value: 0.711 vs. 0.618; p < 0.001] and LTP nomogram (C‐index value: 0.701 vs. 0.612; p < 0.001) were significantly superior for risk stratification than the TNM staging. These results were supported in the validation group with a C‐index value of 0.753 and 0.738 for the ETP and LTP nomograms, respectively. High‐risk patients defined by ETP/LTP nomograms had shorter progression‐free survival than low‐risk patients (all p < 0.001).Conclusion: The established nomograms can help in ELP or LTP risk stratification for NPC patients. Our current results might also provide insights into individualized treatment decisions and designing surveillance strategies for NPC patients.